Dermira (NASDAQ:DERM) was downgraded by Zacks Investment Research from a “hold” rating to a “sell” rating in a report issued on Tuesday.
According to Zacks, “Dermira, Inc. is a specialty biopharmaceutical company. It is focused on bringing medical dermatology products to dermatologists and their patients. The Company markets topical small molecule therapeutics that target acne, sebaceous gland hyperactivity, and inflammatory skin diseases. Its late-stage product candidates comprise Cimzia which has completed Phase II clinical trials for the treatment of moderate-to-severe plaque psoriasis; DRM04 that is in a Phase IIb clinical trial for the treatment of hyperhidrosis or excessive sweating; and DRM01 which has completed a Phase IIa clinical trial for the treatment of acne. Dermira, Inc. is headquartered in Redwood City, California. “
DERM has been the subject of several other research reports. Cantor Fitzgerald set a $45.00 price target on Dermira and gave the stock a “buy” rating in a research report on Wednesday, November 29th. BidaskClub raised Dermira from a “sell” rating to a “hold” rating in a research report on Saturday, December 2nd. Guggenheim began coverage on Dermira in a research report on Tuesday, December 5th. They set a “buy” rating for the company. Mizuho dropped their price target on Dermira from $43.00 to $39.00 and set a “buy” rating for the company in a research report on Tuesday, December 12th. Finally, Leerink Swann raised their price target on Dermira from $42.00 to $48.00 and gave the stock an “outperform” rating in a research report on Wednesday, January 17th. Three research analysts have rated the stock with a sell rating, one has assigned a hold rating and six have issued a buy rating to the company. Dermira currently has a consensus rating of “Hold” and a consensus target price of $42.17.
Dermira (NASDAQ:DERM) last issued its quarterly earnings data on Thursday, February 22nd. The biopharmaceutical company reported ($1.34) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.25) by ($0.09). The firm had revenue of $1.34 million for the quarter, compared to analyst estimates of $1.10 million. Dermira had a negative return on equity of 62.07% and a negative net margin of 6,678.29%. analysts predict that Dermira will post -4.64 EPS for the current year.
In other news, SVP Christopher M. Griffith sold 18,458 shares of Dermira stock in a transaction on Tuesday, January 2nd. The stock was sold at an average price of $27.05, for a total value of $499,288.90. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, insider Eugene A. Bauer sold 3,000 shares of Dermira stock in a transaction on Monday, December 18th. The shares were sold at an average price of $27.34, for a total value of $82,020.00. The disclosure for this sale can be found here. In the last ninety days, insiders sold 34,258 shares of company stock valued at $935,153. Company insiders own 13.30% of the company’s stock.
Several large investors have recently made changes to their positions in DERM. Jennison Associates LLC grew its position in Dermira by 0.3% during the third quarter. Jennison Associates LLC now owns 2,640,740 shares of the biopharmaceutical company’s stock valued at $71,300,000 after acquiring an additional 7,746 shares during the period. Vanguard Group Inc. grew its position in Dermira by 9.8% during the second quarter. Vanguard Group Inc. now owns 1,397,857 shares of the biopharmaceutical company’s stock valued at $40,735,000 after acquiring an additional 125,157 shares during the period. Millennium Management LLC purchased a new stake in Dermira during the fourth quarter valued at about $25,084,000. Franklin Resources Inc. purchased a new stake in Dermira during the fourth quarter valued at about $24,820,000. Finally, State Street Corp grew its position in Dermira by 38.4% during the second quarter. State Street Corp now owns 821,748 shares of the biopharmaceutical company’s stock valued at $23,946,000 after acquiring an additional 228,093 shares during the period. 95.27% of the stock is owned by institutional investors and hedge funds.
Dermira, Inc is a biopharmaceutical company. The Company is focused on the development of therapeutic solutions in medical dermatology to treat skin conditions, such as hyperhidrosis, psoriasis and acne. Its portfolio includes three late-stage product candidates: Cimzia (certolizumab pegol), glycopyrronium tosylate and olumacostat glasaretil.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Dermira Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Dermira and related companies with MarketBeat.com's FREE daily email newsletter.